Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 33,093 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 1 Interventional

Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance

NCT01642030
View directory record Official record
Conditions
Opioid Dependence, Pain, Addiction
Interventions
Placebo, Hydromorphone, Buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Atorvastatin for Orthopedic Surgery Patients

NCT02197065
View directory record Official record
Conditions
Hip Fracture, Myocardial Ischemia, Inflammation
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
65 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy

NCT02770365
View directory record Official record
Conditions
Atrophy
Interventions
estrace cream (Perrigo), estrace cream (Reference), Placebo cream
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 24, 2026, 10:04 PM EDT
Withdrawn Phase 1 Interventional

A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis

NCT06260267
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Microbiota suspension, Microbiota capsule, Placebo suspension, Placebo capsule
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
North Little Rock, Arkansas • Hamden, Connecticut • Inverness, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2024 · Synced Oct 24, 2026, 10:04 PM EDT
Terminated Phase 2 Interventional Results available

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

NCT04454567
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ABI-H0731, Placebo, NrtI
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Pasadena, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 24, 2026, 10:04 PM EDT
Not listed Not applicable Interventional

The Effects of Gentle Movements at the Ankle in Individuals With Diminished Range of Motion

NCT01119092
View directory record Official record
Conditions
Lateral Ankle Sprain
Interventions
Sham ("laying of hands") intervention, Grade IV AP joint mobilizations
Other
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 24, 2026, 10:04 PM EDT
Active, not recruiting Phase 2 Interventional

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

NCT05034536
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Pembrolizumab, Infliximab, Placebo, Relatlimab, Nivolumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men

NCT06542536
View directory record Official record
Conditions
Obesity
Interventions
Monlunabant, Placebo (monlunabant)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 24, 2026, 10:04 PM EDT
Terminated Phase 4 Interventional Results available

Brief Intervention to Reduce Fear of Public Speaking

NCT02790736
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
propranolol, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 24, 2026, 10:04 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Safety and Tolerability Evaluation of IgG Binding Protein LT

NCT07824011
View directory record Official record
Conditions
Safety and Tolerability in Healthy Volunteers
Interventions
IgG Binding Protein LT, Placebo
Dietary Supplement
Lead sponsor
Bactolife A/S
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 24, 2026, 10:04 PM EDT
Terminated Phase 4 Interventional Results available

Does Topical Ophthalmic Anesthetic Prior to Probing and Irrigation Decrease Pain?

NCT04229771
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Oct 24, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

NCT07589634
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Ramantamig, Tocilizumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Goodyear, Arizona • Beverly Hills, California • Irvine, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Bicarbonate Administration in Kidney Transplant Recipients

NCT03428464
View directory record Official record
Conditions
Kidney Transplant; Complications, Metabolic Acidosis
Interventions
Sodium Bicarbonate, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 24, 2026, 10:04 PM EDT
Withdrawn Phase 1 Interventional

A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure

NCT00487799
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Ularitide
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
San Diego, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs

NCT00633399
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Ziprasidone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

Dextromethorphan in Fibromyalgia

NCT03538054
View directory record Official record
Conditions
Fibromyalgia
Interventions
Dextromethorphan, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
23 Years to 65 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 24, 2026, 10:04 PM EDT
Terminated Not applicable Interventional

A Novel Formulation of Pasteurized Maple Cough Syrup Compared With Placebo on Nocturnal Cough and Sleep Quality in Infants With Upper Respiratory Infection

NCT01588249
View directory record Official record
Conditions
Cough, Upper Respiratory Infection, Nocturnal Cough
Interventions
Pasteurized maple syrup, Placebo
Dietary Supplement
Lead sponsor
Zarbee's Inc.
Industry
Eligibility
Up to 12 Months
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Draper, Utah • South Jordan, Utah • West Jordan, Utah
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects

NCT01365338
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, PF-04958242
Drug
Lead sponsor
Biogen
Industry
Eligibility
21 Years to 55 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 24, 2019 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Randomized Therapy In Status Epilepticus

NCT04391569
View directory record Official record
Conditions
Status Epilepticus
Interventions
Ganaxolone, Placebo
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

The Impact of Perioperative Ketamine Infusion on Surgical Recovery

NCT04625283
View directory record Official record
Conditions
Opioid Use, Enhanced Recovery After Surgery, Anesthesia, Ketamine, Pain, Postoperative
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,570 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 2 Interventional

A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.

NCT03636347
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency, Emphysema, COPD
Interventions
Placebo Oral Tablet, Alvelestat oral tablet - dose 1, Alvelestat oral tablet - dose 2
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 24, 2026, 10:04 PM EDT
Terminated Phase 2 Interventional

Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

NCT02877641
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Muscle Weakness
Interventions
Cholecalciferol, Laboratory Biomarker Analysis, Multivitamin, Placebo, Questionnaire Administration
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 24, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)

NCT02709538
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
GSP 301 NS, GSP 301 Placebo NS pH 3.7, GSP 301 Placebo NS pH 7.0
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
34
States / cities
Hot Springs, Arkansas • Encinitas, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 24, 2026, 10:04 PM EDT